This phase II trial is trying to determine if a new immunotherapy (Blinatumomab) can help treat patients with Acute Lymphoblastic Leukaemia.
This trial is treating patients with acute lymphoblastic leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Other Non-Commercial Sponsor
Eligible patients will receive continuous intravenous Blinatumomab over two 28-day cycles, using an infusion device that will be programmed and monitored by the nursing staff.
Recruiting Hospitals Read More